French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) announced late Wednesday that it has received US Food and Drug Administration (FDA) approval for Infilbray (venglustat), an oral medicine for treating neurological manifestations of Type 3 Gaucher disease (GD3) in adults and children weighing at least 15 kg.
The once-daily glucosylceramide synthase inhibitor is designed to cross the blood-brain barrier and address neurological complications associated with the rare genetic disorder.
This approval is supported by positive results from the Phase 3 LEAP2MONO study, which demonstrated statistically significant superiority over enzyme replacement therapy imiglucerase across multiple neurological endpoints. Patients receiving Infilbray showed improvements in cognitive function, coordination and balance after 52 weeks of treatment.
Infilbray has received breakthrough therapy, rare paediatric disease and fast-track designations in the US, alongside orphan drug designations in the US, EU and Japan. Sanofi is pursuing further regulatory approvals, with applications planned across additional markets in 2026 and 2027. The medicine remains under regulatory review in the EU, Japan and other jurisdictions.
Ten63 Therapeutics launches BEYOND-Alpha early adopter programme
Eloxx Pharmaceuticals publishes Phase 2a exaluren data in nonsense mutation Alport syndrome
Bristol Myers Squibb reports first Phase 3 data for KarXT in Alzheimer's-related psychosis
Pfizer signs licensing agreement with Starna Therapeutics worth up to USD2.63bn
Inhibrx updates clinical data for ozekibart (INBRX-109) in Ewing sarcoma
Dicot Pharma initiates phase 2b clinical study of erectile dysfunction drug candidate
Sobi's Tryngolza for severe hypertriglyceridaemia receives EU approval
Oncoinvent reports favourable interim safety results for Radspherin in phase 2 ovarian cancer trial
Rakuten Medical launches Phase 1 first-in-human trial of PD-L1-targeted RM-0256 photoimmunotherapy
BioArctic and Eisai report positive five-year data for Leqembi in early Alzheimer's disease
Akeso submits sNDA for ivonescimab chemotherapy combination in first-line biliary tract cancer
AstraZeneca rare disease unit secures US and EU approvals for Klygefa in myasthenia gravis
Genentech secures first FDA approval for primary membranous nephropathy treatment